Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management  

Hear four panelists discuss the role of integrated evidence generation in healthcare, focusing on its impact on patient outcomes and healthcare decision-making.

To influence patient outcomes, evidence must address unmet needs, align with the medical and commercial strategy, and provide value to healthcare providers (HCPs) and patients. Integrated evidence generation planning that encompasses real-world evidence (RWE), health economics and outcomes research (HEOR), and clinical studies is the best approach for gathering and synthesizing data to support clinical and payer decision-making. Cross-functional teams that span Market Access, HEOR, RWE, Commercial, and Medical Affairs blend broad perspectives to foster value-based integrated planning. Now that Medical Affairs contributes earlier in the integrated evidence generation planning process, patient and HCP evidence needs can be incorporated into studies earlier, ensuring more meaningful and actionable data generation. Through such cross-functional partnership, the hope is that integrated evidence generation planning can become more targeted, valuable, and efficient in generating data that will fulfill disease- and asset-driven unmet needs.